Calpis

Calpis is a Japanese company, currently a subsidiary of Asahi Group Holdings, that specializes in the development of functional foods and beverages based on lactic acid bacteria fermentation. The company is globally recognized for its research into probiotics and bioactive peptides, particularly those derived from its proprietary fermentation processes. Its flagship life science products include AmealPeptide, a clinically validated ingredient for blood pressure management, and various probiotic strains targeting the gut-brain axis and metabolic health. Calpis continues to leverage its century-long expertise in microbiology to innovate in the fields of preventive medicine and wellness. The company's R&D efforts are primarily focused on the systemic health benefits of fermented milk and its constituent components.